Date of Publication: 19-Feb-2026
INTELLIGENCE OVERVIEW
Agency: EMA
The European Medicines Agency (EMA) has published its updated pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2026. The document provides outcomes adopted by the Committee for Veterinary Medicinal Products (CVMP), including safety-related updates to product information such as the Summary of Product Characteristics (SPC) and Package Leaflets.
These recommendations include safety information revisions for several veterinary products, including vaccines and antiparasitic medicines. The updates focus on hypersensitivity reactions, injection site reactions, systemic adverse events, and safety precautions for both animals and persons administering the products. Such updates ensure continuous monitoring and transparency of veterinary medicinal product safety in the EU.
Industry Impact
These pharmacovigilance recommendations reinforce the importance of continuous safety monitoring and regulatory compliance for veterinary Marketing Authorisation Holders. Companies must assess and implement required updates to product information, labelling, and risk communication in line with CVMP recommendations.
For veterinary pharmaceutical manufacturers, these updates support proactive pharmacovigilance planning, regulatory compliance, and lifecycle management, ensuring the continued safe use of veterinary medicinal products and alignment with EU regulatory expectations.
KEYWORDS: Veterinary Pharmacovigilance, Compliance, Recommendations
REFERENCE: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pharmacovigilance-related-regulatory-recommendations-centrally-authorised-veterinary-medicinal-products-during-2026_en.pdf https://www.ema.europa.eu/en/news-events/whats-new